- Report
- March 2024
- 185 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- September 2023
- 120 Pages
Global
From €5752EUR$5,950USD£4,941GBP
- Report
- April 2024
- 92 Pages
Global
From €5414EUR$5,600USD£4,650GBP
- Report
- October 2023
- 147 Pages
Global
From €2416EUR$2,499USD£2,075GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1208EUR$1,250USD£1,038GBP
- Report
- October 2023
- 190 Pages
Global
From €4737EUR$4,900USD£4,069GBP
- Report
- December 2023
- 344 Pages
Global
€4829EUR$4,995USD£4,148GBP
- Report
- August 2022
- 117 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- January 2022
- 200 Pages
Global
From €7251EUR$7,500USD£6,228GBP
- Report
- January 2022
- 60 Pages
Global
From €3819EUR$3,950USD£3,280GBP
- Report
- September 2020
- 120 Pages
Global
From €2417EUR$2,500USD£2,076GBP
- Report
- October 2022
- 125 Pages
Global
From €2417EUR$2,500USD£2,076GBP
- Report
- May 2022
- 39 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Drug Pipelines
- November 2019
- 37 Pages
Global
From €1934EUR$2,000USD£1,661GBP
Xerostomia Drug is a type of drug used to treat dry mouth, a condition caused by a decrease in saliva production. Xerostomia is a common symptom of immune disorders, such as Sjogren's Syndrome, HIV/AIDS, and lupus. Xerostomia drugs are designed to increase saliva production and reduce the discomfort associated with dry mouth. These drugs can be taken orally, applied topically, or administered through a nasal spray. Commonly used xerostomia drugs include pilocarpine, cevimeline, and bromhexine.
The xerostomia drug market is a rapidly growing segment of the immune disorder drug market. It is driven by the increasing prevalence of immune disorders, as well as the development of new drugs to treat dry mouth. Companies in the xerostomia drug market include GlaxoSmithKline, Novartis, Merck, Pfizer, and Sun Pharmaceuticals. Show Less Read more
